Innovative drug approvals vs First-in-class drug approvals in China
In 2025, innovative drug approvals in China stood at 76, against 11 for first-in-class drug approvals.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Innovative drug approvals and First-in-class drug approvals
Unit: count · 6 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Innovative drug approvals | 2025 | Actual | 76 |
| Innovative drug approvals | 2024 | Actual | 48 |
| First-in-class drug approvals | 2025 | Actual | 11 |
| First-in-class drug approvals | 2024 | Actual | 48 |
| First-in-class drug approvals | 2023 | Actual | 40 |
| First-in-class drug approvals | 2022 | Actual | 21 |
Shared periods
Side by side
Only 2 periods are published for both series in China. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Innovative drug approvals
Total number of innovative pharmaceutical products granted regulatory marketing authorization.
2 observations in China · source organisations: NHSA
First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
4 observations in China · source organisations: NMPA, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring